Aliskiren
Aliskiren is a direct renin inhibitor used to treat high blood pressure (hypertension). It works by blocking the renin enzyme in the renin-angiotensin-aldosterone system (RAAS), preventing the conversion of angiotensinogen to angiotensin I, which reduces angiotensin II levels and lowers blood pressure. It may be used alone or in combination with other antihypertensive agents.
Aliskiren is an antihypertensive medication that works by directly inhibiting renin to reduce blood pressure.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- C09XA02
- RxNorm
- 325646
- Generic
- Aliskiren
- Class
- atc-c09
- Brands
- Tekturna HCT, Tekturna
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- tablet
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 150mg once daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- not established
- Maximum
- consult physician
- Frequency
- not applicable
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 150mg once daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
8 groupspregnancy
overallavoid use
avoid use during pregnancy unless benefits outweigh risks. Aliskiren acts on the renin-angiotensin system which is critical for fetal development
regular fetal monitoring including ultrasound
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
breastfeedingavoid use
discontinue breastfeeding or discontinue the drug
monitor infant for hypotension and renal function
Use of this medication in this population requires careful consideration of risks and benefits.
geriatric
elderlystart at low end of dosing range
use with caution in patients over 65 years. Monitor renal function and blood pressure closely
regular monitoring of blood pressure and renal function
Use with caution and monitor for adverse effects.
pediatric_age
children adolescentsnot recommended
not recommended for use in children and adolescents under 18 years of age. Safety and efficacy not established
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
renal_impairment
severeavoid in severe impairment
contraindicated in patients with severe renal impairment (CrCl <30 mL/min). Use with caution in moderate impairment
monitor renal function and serum potassium regularly
Use of this medication in this population requires careful consideration of risks and benefits.
renal_impairment
moderatereduce dose if needed
use with caution in patients with moderate renal impairment (CrCl 30-60 mL/min). Start at lower dose
monitor renal function and potassium levels
Use with caution and monitor for adverse effects.
hepatic_impairment
mild moderateno adjustment needed
no dose adjustment required for mild to moderate hepatic impairment
standard monitoring
hepatic_impairment
severeuse with caution
use with caution in severe hepatic impairment due to limited data
monitor liver function tests
Use with caution and monitor for adverse effects.
Statistics and clinical data
FDA approval year
FDA approval date for Aliskiren
Drug class
Pharmacological classification
Common uses
Primary therapeutic indication
Mechanism of action
Pharmacodynamic properties
Treatment of essential hypertension (high blood pressure) in adults. It may be prescribed alone or combined with other blood pressure medications such as thiazide diuretics or calcium channel blockers.
Aliskiren is a direct renin inhibitor that binds to the active site of renin, blocking the conversion of angiotensinogen to angiotensin I. This reduces the production of angiotensin II, a potent vasoconstrictor, leading to decreased vascular resistance and lower blood pressure.
Contraindicated during pregnancy due to risk of fetal harm. Not recommended in combination with ACE inhibitors or ARBs in patients with diabetes. May cause hyperkalemia, especially when used with other RAAS inhibitors. Common side effects include diarrhea, dizziness, and headache. Not typically used as first-line therapy.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy